UY31674A1 - Derivado heterocíclico fusionado y su uso - Google Patents

Derivado heterocíclico fusionado y su uso

Info

Publication number
UY31674A1
UY31674A1 UY031674A UY31674A UY31674A1 UY 31674 A1 UY31674 A1 UY 31674A1 UY 031674 A UY031674 A UY 031674A UY 31674 A UY31674 A UY 31674A UY 31674 A1 UY31674 A1 UY 31674A1
Authority
UY
Uruguay
Prior art keywords
fused heterocyclic
ring
heterocyclic derivative
provides
present
Prior art date
Application number
UY031674A
Other languages
English (en)
Inventor
Yuya Oguro
Shigeru Kondo
Satoshi Sasaki
Nobuhiro Fujii
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of UY31674A1 publication Critical patent/UY31674A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención provee un compuesto que tiene una actividad inhibidora de Smo superior y baja toxicidad, que es suficientemente satisfactoria como producto farmacéutico. La presente invención provee un compuesto representado por la fórmula en el cual anillo A es anillo de 5 a 7 miembros que tiene sustituyente (s) en forma opcional, donde los sustituyentes están unidos en forma opcional entre sí para formar un anillo.
UY031674A 2005-07-05 2009-02-25 Derivado heterocíclico fusionado y su uso UY31674A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005196866 2005-07-05
JP2006054102 2006-02-28

Publications (1)

Publication Number Publication Date
UY31674A1 true UY31674A1 (es) 2009-08-31

Family

ID=37055938

Family Applications (1)

Application Number Title Priority Date Filing Date
UY031674A UY31674A1 (es) 2005-07-05 2009-02-25 Derivado heterocíclico fusionado y su uso

Country Status (8)

Country Link
US (1) US20090137580A1 (es)
EP (1) EP1904498A1 (es)
JP (1) JP2009500295A (es)
AR (1) AR055071A1 (es)
PE (1) PE20070174A1 (es)
TW (1) TW200740820A (es)
UY (1) UY31674A1 (es)
WO (1) WO2007004749A1 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101378716B1 (ko) * 2005-05-20 2014-04-10 메틸진 인코포레이티드 Ｖｅｇｆ 수용체 및 ｈｇｆ 수용체 신호전달의 억제제
CN101296928B (zh) * 2005-10-28 2011-01-19 Irm责任有限公司 作为蛋白激酶抑制剂的化合物和组合物
TW200730527A (en) * 2005-12-02 2007-08-16 Takeda Pharmaceuticals Co Fused heterocyclic compound
NZ551796A (en) * 2006-12-05 2009-07-31 Craig Robert Stuart Bump-resistant pin tumbler lock
EP2099444A4 (en) 2006-12-14 2012-11-07 Nps Pharma Inc USE OF D-SERIN DERIVATIVES FOR THE TREATMENT OF ANTIBODIES
CN101932586A (zh) * 2007-08-29 2010-12-29 梅赛尔基因股份有限公司 蛋白酪氨酸激酶活性的抑制
JPWO2009096435A1 (ja) * 2008-01-29 2011-05-26 武田薬品工業株式会社 縮合複素環誘導体およびその用途
CA2717816A1 (en) * 2008-03-05 2009-09-11 Tetsuyuki Uno Inhibitors of protein tyrosine kinase activity
WO2009136663A1 (en) 2008-05-08 2009-11-12 Takeda Pharmaceutical Company Limited Fused heterocyclic derivatives and use thereof
WO2010108503A1 (en) 2009-03-24 2010-09-30 Life & Brain Gmbh Promotion of neuronal integration in neural stem cell grafts
WO2011056895A1 (en) * 2009-11-03 2011-05-12 University Of Notre Dame Du Lac Ionic liquids comprising heteraromatic anions
US8912184B1 (en) 2010-03-01 2014-12-16 Alzheimer's Institute Of America, Inc. Therapeutic and diagnostic methods
JP2013522171A (ja) * 2010-03-01 2013-06-13 ミレクシス， インコーポレイテッド 化合物およびその治療用途
JP2013523715A (ja) 2010-03-31 2013-06-17 アクテリオン ファーマシューティカルズ リミテッド イソキノリン−３−イル尿素誘導体
WO2012008564A1 (ja) * 2010-07-16 2012-01-19 協和発酵キリン株式会社 含窒素芳香族複素環誘導体
AR088729A1 (es) 2011-03-29 2014-07-02 Actelion Pharmaceuticals Ltd Derivados de 3-ureidoisoquinolin-8-ilo y una composicion farmaceutica
BR112014010551A2 (pt) * 2011-10-31 2017-05-02 Glaxosmithkline Ip Dev Ltd composição adequada para a reconstituição em uma suspensão aquosa, pó para a combinação direta para o uso em composição farmacêutica, formulação farmacêutica de suspensão oral, e, suspensão oral
BR112015024671A2 (pt) 2013-04-02 2017-07-18 Respivert Ltd derivados de ureia úteis como inibidores de quinase
RS58361B1 (sr) * 2013-07-31 2019-03-29 Merck Patent Gmbh Piridini, pirimidini i pirazini, kao inhibitori btk i njihova upotreba
WO2015048765A1 (en) 2013-09-30 2015-04-02 University Of Notre Dame Du Lac Compounds, complexes, compositions, methods and systems for heating and cooling
US10086331B2 (en) 2013-11-05 2018-10-02 University Of Notre Dame Du Lac Carbon dioxide capture using phase change ionic liquids
EP3083604A1 (en) 2013-12-20 2016-10-26 Respivert Limited Urea derivatives useful as kinase inhibitors
MA40774A (fr) 2014-10-01 2017-08-08 Respivert Ltd Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38
WO2017038873A1 (ja) * 2015-08-31 2017-03-09 東レ株式会社 尿素誘導体及びその用途
JP6995774B2 (ja) 2016-04-06 2022-02-21 オクラー アクイジションズ リミテッド キナーゼ阻害剤
US10196378B2 (en) * 2016-08-25 2019-02-05 The Regents Of The University Of Michigan Inhibitors of BCR-ABL mutants and use thereof
CN109180677A (zh) * 2017-06-30 2019-01-11 厦门大学 取代芳基醚类化合物、其制备方法、药用组合物及其应用
EA202192575A1 (ru) 2019-03-21 2022-01-14 Онксео Соединения dbait в сочетании с ингибиторами киназ для лечения рака
CN110128299B (zh) * 2019-05-13 2020-11-10 浙江大学 一种二苯基脲类抗肿瘤小分子抑制剂及其制备方法
WO2020245208A1 (en) 2019-06-04 2020-12-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of cd9 as a biomarker and as a biotarget in glomerulonephritis or glomerulosclerosis
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN116789670A (zh) * 2022-03-17 2023-09-22 中国科学院合肥物质科学研究院 一种选择性csf1r抑制剂及其用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL112249A (en) * 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
AR004010A1 (es) * 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
JP2000515136A (ja) * 1996-07-13 2000-11-14 グラクソ、グループ、リミテッド プロテインチロシンキナーゼ阻害剤としての二環式ヘテロ芳香族化合物
BR9711970A (pt) 1996-08-28 1999-08-24 Pfizer Derivados 6,5-substitu¡do-heterobic¡clicos
US6797823B1 (en) * 1999-01-22 2004-09-28 Kirin Beer Kabushiki Kaisha Quinoline derivatives and quinazoline derivatives
ES2360933T3 (es) 2000-04-27 2011-06-10 Astellas Pharma Inc. Derivados de heteroarilo condensados.
EP1777218B1 (en) * 2000-10-20 2008-12-31 Eisai R&D Management Co., Ltd. Process for the preparation of 4-phenoxy quinoline derivatives
TWI324154B (es) * 2001-04-27 2010-05-01 Kyowa Hakko Kirin Co Ltd
MEP8409A (en) * 2004-06-02 2011-12-20 Fused heterocyclic compound

Also Published As

Publication number Publication date
TW200740820A (en) 2007-11-01
US20090137580A1 (en) 2009-05-28
AR055071A1 (es) 2007-08-01
EP1904498A1 (en) 2008-04-02
PE20070174A1 (es) 2007-03-12
JP2009500295A (ja) 2009-01-08
WO2007004749A1 (en) 2007-01-11

Similar Documents

Publication Publication Date Title
UY31674A1 (es) Derivado heterocíclico fusionado y su uso
CR11661A (es) Derivado heterociclico fusionado y su uso
CR10148A (es) Derivados de las benzamidas y heteroarenos
ECSP077271A (es) Derivados de pirimidina
PA8791801A1 (es) Compuestos de pirazol
ECSP077259A (es) Derivados de pirimidina
CU20110078A7 (es) Compuestos de carbazol
BRPI0408347B8 (pt) derivados de pirimidina, seu uso, e composição e combinação farmacêuticas
EA201000544A1 (ru) Производные спирогетероциклического пирролидиндиона, применимые в качестве пестицидов
CR10968A (es) Nuevos derivados de 3-amino-pirrolo[3,4-c]pirazol -5(1h, 4h, 6h) carbaldehido
ECSP088367A (es) Derivados de bifenilo y su uso en el tratamiento de la hepatitis c
CR11518A (es) Compuestos de carbamoilo como inhibidores de dgat1 190
ECSP10010561A (es) Pirimidin-5-carboxamidas sustituidas 281
ECSP109856A (es) Derivados de oxadiazol y su uso como potenciadores de los receptores metabotrópicos de glutamato - 842
CR9980A (es) Imidazolinas 4,4,5,5 tetrasustituidas
DOP2011000176A (es) Compuestos organicos
CR9587A (es) Derivados de piridazina
CR8451A (es) Uso de derivados de n-arilhidracina para combatir pestes
ECSP10010334A (es) Derivados de quinolina y su uso como fungicidas
CU20100238A7 (es) Derivados de isoxazol y su uso como potenciadores de los receptores metabotrópicos de glutamato
ATE445593T1 (de) Acetylenderivate
GB0508318D0 (en) Organic compounds
TN2010000061A1 (en) Tricyclic bridged cyclopentanedione derivatives as herbicides
GT200600081A (es) Derivados de acetilenno
GT200600366A (es) Compuestos de imidazol sustituido como inhibidores de ksp

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20181017